228 related articles for article (PubMed ID: 34578259)
1. Specificity, Safety, Efficacy of EGFRvIII-Retargeted Oncolytic HSV for Xenotransplanted Human Glioblastoma.
Appolloni I; Alessandrini F; Menotti L; Avitabile E; Marubbi D; Piga N; Ceresa D; Piaggio F; Campadelli-Fiume G; Malatesta P
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578259
[TBL] [Abstract][Full Text] [Related]
2. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus.
Uchida H; Marzulli M; Nakano K; Goins WF; Chan J; Hong CS; Mazzacurati L; Yoo JY; Haseley A; Nakashima H; Baek H; Kwon H; Kumagai I; Kuroki M; Kaur B; Chiocca EA; Grandi P; Cohen JB; Glorioso JC
Mol Ther; 2013 Mar; 21(3):561-9. PubMed ID: 23070115
[TBL] [Abstract][Full Text] [Related]
3. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
4. Antibody Screening System Using a Herpes Simplex Virus (HSV)-Based Probe To Identify a Novel Target for Receptor-Retargeted Oncolytic HSVs.
Ikeda H; Uchida H; Okubo Y; Shibata T; Sasaki Y; Suzuki T; Hamada-Uematsu M; Hamasaki R; Okuda K; Yamaguchi M; Kojima M; Tanaka M; Hamada H; Tahara H
J Virol; 2021 Apr; 95(9):. PubMed ID: 33627393
[TBL] [Abstract][Full Text] [Related]
5. HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses.
Menotti L; Avitabile E; Gatta V; Malatesta P; Petrovic B; Campadelli-Fiume G
Viruses; 2018 Jun; 10(7):. PubMed ID: 29966356
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
7. Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.
Fukuhara H; Takeshima Y; Todo T
Cancer Sci; 2021 Aug; 112(8):3293-3301. PubMed ID: 34036669
[TBL] [Abstract][Full Text] [Related]
8. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV.
Mazzacurati L; Marzulli M; Reinhart B; Miyagawa Y; Uchida H; Goins WF; Li A; Kaur B; Caligiuri M; Cripe T; Chiocca EA; Amankulor N; Cohen JB; Glorioso JC; Grandi P
Mol Ther; 2015 Jan; 23(1):99-107. PubMed ID: 25200130
[TBL] [Abstract][Full Text] [Related]
9. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
10. Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model.
Alessandrini F; Menotti L; Avitabile E; Appolloni I; Ceresa D; Marubbi D; Campadelli-Fiume G; Malatesta P
Oncogene; 2019 Jun; 38(23):4467-4479. PubMed ID: 30755732
[TBL] [Abstract][Full Text] [Related]
11. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.
Grandi P; Fernandez J; Szentirmai O; Carter R; Gianni D; Sena-Esteves M; Breakefield XO
Cancer Gene Ther; 2010 Sep; 17(9):655-63. PubMed ID: 20508670
[TBL] [Abstract][Full Text] [Related]
12. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
14. Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma.
Gambini E; Reisoli E; Appolloni I; Gatta V; Campadelli-Fiume G; Menotti L; Malatesta P
Mol Ther; 2012 May; 20(5):994-1001. PubMed ID: 22354378
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-sensitive oncolytic measles viruses for cancer-specific vector tropism.
Leber MF; Bossow S; Leonard VH; Zaoui K; Grossardt C; Frenzke M; Miest T; Sawall S; Cattaneo R; von Kalle C; Ungerechts G
Mol Ther; 2011 Jun; 19(6):1097-106. PubMed ID: 21468006
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic adenovirus retargeted to Delta-EGFR induces selective antiglioma activity.
Piao Y; Jiang H; Alemany R; Krasnykh V; Marini FC; Xu J; Alonso MM; Conrad CA; Aldape KD; Gomez-Manzano C; Fueyo J
Cancer Gene Ther; 2009 Mar; 16(3):256-65. PubMed ID: 18927600
[TBL] [Abstract][Full Text] [Related]
17. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
[TBL] [Abstract][Full Text] [Related]
18. Incorporation of the B18R gene of vaccinia virus into an oncolytic herpes simplex virus improves antitumor activity.
Fu X; Rivera A; Tao L; Zhang X
Mol Ther; 2012 Oct; 20(10):1871-81. PubMed ID: 22692498
[TBL] [Abstract][Full Text] [Related]
19. Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.
Nanni P; Gatta V; Menotti L; De Giovanni C; Ianzano M; Palladini A; Grosso V; Dall'ora M; Croci S; Nicoletti G; Landuzzi L; Iezzi M; Campadelli-Fiume G; Lollini PL
PLoS Pathog; 2013 Jan; 9(1):e1003155. PubMed ID: 23382683
[TBL] [Abstract][Full Text] [Related]
20. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
